The fatal tumor of man’s brain cancer disappears after an experimental trial of drugs

A man with the most deadly form of brain cancer has no signs of the disease after taking an experimental drug.

Ben Trotman was 40 years old when he was diagnosed with Glioblastoma by 2022, the most aggressive cancerous brain tumor. Patients usually live an average of 15 months after the diagnosis and survival rate of five years is only 6.9%.

Trotman was referred to the National Hospital of Neurology and Neurosurgery at University College London Hospitals (UCLH), where he was treated by the UCLH medical oncologist, Dr. Paul Mulholland, as he details in a statement.

The fungus of the old “Pharaoh” curse “shows a promise to kill cancer cells

As the only person enrolled in an essay that was finally closed due to lack of patients, Trotman received a medicine called IPILIMUB, a treatment with directed immunotherapy.

IPILMUMAB is an antibody that joins a protein in immune cells (T cells), preventing cancer cells from suppressing the immune system so that it can then attack and kill cancer, according to the National Cancer Institute.

Trotman also received radiation and chemotherapy. More than two years later, their quarterly explorations do not show signs of cancer.

“It is very unusual to have a clear exploration with glioblastoma, especially when it did not have the monitoring surgery that was planned to eliminate the whole tumor that was initially visible in the explorations,” said his oncologist, Mulholland, in the statement.

“We felt that we were lucky enough in an otherwise devastating situation.”

“We hope that immunotherapy and tracking treatment that will have its tumor at bay, and so far, we are happy to see.”

Two months after receiving the IPILIMUB, Trotman married his wife, Emily. In April 2025, they welcomed their daughter, Mabel.

“Getting this diagnosis was the most traumatic experience: we started to see that it had gone from being perfectly healthy to having months to live,” said Emily Trotman in the statement.

Click here to get the Fox News app

“If we had not met Dr. Mulholland, that would have been for us. We felt we had a lucky break in a highly devastating situation.”

Ben Trotman added: “Obviously we do not know what the future is, but having had the treatment with immunotherapy and obtaining these encouraging exploration results [us] A little hope. “

“We are focused on rebuilding the life we thought we had lost and enjoying being parents.”

Mulholland and his team have opened another clinical trial for patients who have recently been diagnosed with glioblastoma.

Click here to register -you are in our health newsletter

Sixteen patients will be recruited for the test, which is sponsored by UCL. The treatment will be administered in the NIHR UCLH clinical research installation and the National Hospital of Neurology and Neurosurgery, according to the statement.

Patients will receive IPilimumab before proceeding to standard treatments that may include surgery, radiotherapy and chemotherapy.

“The crucial element of this essay is that patients will have their immune system driven by the drug before they have any other treatment, when they are adequate and well enough to tolerate immunotherapy,” Mulholland said in the statement.

The Win-Glio-Sobrenomed “Margaret” trial-is funded by the effort of Dame Siobhain McDonagh, sister of Margaret McDonagh, a woman from London who died of Glioblastoma in 2023 and was treated by Mulholland.

For more health items, visit www.foxnews.com/health

Ben said he is “delighted” for the new trial to move forward with the same immunotherapy drug he received.

“It will give hope to the newly diagnosed people of glioblastoma.”